Objective. A proportion of RA and SLE patients treated with standard doses of rituximab (RTX) display inefficient B cell deletion and poor clinical responses that can be augmented by delivering higher doses, indicating that standard-dose RTX is a sub-optimal therapy in these patients. This study aimed to investigate whether better responses could be achieved with mechanistically different anti-CD20 mAbs.
Introduction
Incomplete B cell depletion following treatment with the anti-CD20 mAb rituximab (RTX) is associated with poor clinical response in both RA [1] and SLE [2] , whereas enhanced B cell depletion achieved using additional doses of RTX in RA [3] and prolonged duration of depletion are associated with a better clinical response in SLE [4] . Therefore, these data indicate that achieving complete, durable B cell depletion will improve clinical response in both RA and SLE. ). Poor clinical response to RTX in both RA and SLE is associated with a higher number and/ or frequency of CD27 + memory cells [1, 2, 5] and also with DN B cells in RA [5] , suggesting that resistance to depletion of different B cell subpopulations is clinically relevant [6] . Anti-CD20 mAbs evoke distinct cytotoxic mechanisms: complement-dependent cellular cytotoxicity (CDC), Fc gamma receptor (FcgR)-mediated depletion through cellular effectors including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis, and direct cell death (DCD). Good clinical response to rituximab in both RA [11] and SLE [12] is associated with the higher affinity 158 V polymorphism in CD16a (FcgRIIIa) suggesting that FcgR-mediated mechanisms are important for B cell depletion. Moreover, SLEassociated defects in complement [13] , NK cells [14, 15] and neutrophils [16] and acquired defects in phagocytosis [1618] may impact the efficiency of anti-CD20 mAbs [19] .
Anti-CD20 mAbs can be categorized as types I and II. Type I anti-CD20 mAbs, such as RTX, redistribute CD20 into lipid rafts, a property that facilitates clustering and complement activation, but also mAb internalization, which is partly driven by cis-mediated engagement of FcgRIIb [20, 21] , reducing surface accessible mAb for engagement with FcgR on effector cells [22] such as NK cells, neutrophils and macrophages [23] . Type II mAbs such as obinutuzumab (OBZ, GA101) do not undergo efficient redistribution, clustering or internalization. Accordingly, in follicular and mantle cell lymphoma high target cell expression of FcgRIIb was shown to be associated with poor clinical response to RTX [20, 24] .
Other type I mAbs, ofatumumab and ocrelizumab, have been used in clinical trial settings in RA and/or SLE, respectively [25, 26] . To date, no type II mAb has been used in these diseases. However, OBZ has been used in chronic lymphocytic leukaemia and shown to be more effective than RTX [27] . OBZ has also been glycoengineered with an afucosylated Fc facilitating enhanced affinity for CD16a [28] , which is the basis of its superior potency in NK-mediated ADCC [29] and antibody-dependent cellular phagocytosis [30] . Therefore, data on the pre-clinical activity of RTX and OBZ in RA and SLE would be of clear clinical importance to understanding whether OBZ may at least partly overcome autoimmune disease-related resistance mechanisms.
Our previous work showed that internalization of RTX compromised its ability to delete B cells in vitro and that glycosylated OBZ was superior to RTX in whole blood B cell depletion assays in both RA and SLE [31] . Here, we compared the ability of RTX and OBZ to evoke different effector mechanisms and delete target B cells from patients with RA and SLE. We show that OBZ is at least 2-fold more efficient than RTX at inducing cytotoxicity of these B cells, that it internalizes less rapidly than RTX from the autoimmune B cells, and that it is less efficient than RTX at recruiting complement, but significantly more potent at evoking FcgR-mediated activation of NK cells and neutrophils as well as FcgR-independent direct cell death. We also show that IgD À CD27 + switched memory cells and DN cells express significantly lower levels of CD20 than IgD + CD27 + unswitched memory cells, potentially contributing to their apparent resistance to RTXinduced depletion.
Methods
All participants of this study provided consent according to the Declaration of Helsinki and this study was approved by the National Research Ethics Service committee, London-Bentham. All patients with RA satisfied the ACR/EULAR classification criteria [32] and all patients with SLE met the ACR classification criteria [33] . The patient demographics are shown in the supplementary Tables S1 and S2, available at Rheumatology Online.
Antibodies and reagents
Anti-CD20 mAbs used in the studies include RTX, OBZ and non-glycoengineered, wild-type glycosylated OBZ (OBZ Gly ) and in some experiments OBZ with a mutated Fc portion (P329G LALA) that does not engage any Fcmediated effector functions [34] (OBZ-PG LALA). Roche Innovation Center Zü rich, Switzerland generated all anti-CD20 mAbs except RTX, which was a kind gift from the pharmacy of University College Hospital, UK, and AT10 (FcgRII antagonist) [35] was produced in-house.
Flow cytometry and B cell isolation Whole blood B cell depletion assays Briefly, 300 ml of freshly drawn whole blood anti-coagulated with heparin was incubated with or without mAbs at 1 mg/ml for 24 h at 37 C and 5% CO 2 before analysing with a flow cytometer, as described previously [31] . The percentage B cell depletion was calculated from the proportion of B cells to T cells remaining after treatment and defined as the cytotoxicity index (CTI) as described previously [28, 31] .
Surface fluorescence-quenching assays Surface fluorescence-quenching assays were performed as described previously [23, 31] to assess internalization of mAbs by B cells. Isolated B cells were incubated for 6 h with Alexa-488 conjugated mAbs at a concentration of 5 mg/ml before analysing by flow cytometry.
CDC cytotoxicity assays CDC assays were performed as previously described [36] . Isolated B cells were incubated with mAbs at a concentration of 10 mg/ml for 30 min at 37 C and 5% CO 2 stained with anti-CD19, Av and PI and the frequency of CD19 + Av + PI + cells assessed by flow cytometry. We used freshly collected normal healthy human serum as a source of complement and part of the serum was heat inactivated at 56 C for 30 min to produce heat inactivated serum (HIS). The ability of mAbs to induce CDC was assessed by the relative frequency of CD19 + Av + PI + cells in samples incubated either with normal healthy serum or with HIS.
Direct cell death
Isolated B cells were incubated in RPMI supplemented with 10% heat inactivated fetal calf serum with or without mAbs at a concentration of 10 mg/ml for 6 h at 37 C and 5% CO 2 and stained and analysed as for CDC. The frequency of CD19 + Av + cells in samples incubated with mAbs compared with samples incubated without mAbs represented the ability of mAbs to induce DCD.
NK cell degranulation assays NK cell degranulation was assessed using samples from the whole blood B cell depletion assay by measuring the expression of CD107a or lysosome associated membrane protein 1, which is up-regulated upon activation of NK cells and correlates with NK cell mediated ADCC [37, 38] . The extent of CD16a loss was also used as an indirect measure of NK cell activation [39, 40] .
Neutrophil activation assays
We assessed neutrophil activation in the whole blood assay by measuring increases in the mean fluorescent intensity (MFI) of CD11b or decreases in MFI of CD62L on CD15 + neutrophils by flow cytometry [41, 42] 
Results
Type II mAbs are more efficient than type I at inducing B cell cytotoxicity
To assess the effect of types I and II mAbs on B cell cytotoxicity in RA and SLE samples, whole blood B cell depletion assays were performed as described previously [31] (supplementary Fig. S1 , available at Rheumatology Online). OBZ was >2-fold more efficient than RTX at deleting B cells from patients with RA (n = 31) and SLE (n = 34) and both non-glycomodified OBZ Gly and OBZ were more efficient than RTX, in all samples tested (Fig. 1A and supplementary Table S3 , available at Rheumatology Online). In both RA and SLE, the median CTI of OBZ was significantly greater than the CTI of OBZ Gly and RTX. The CTI of OBZ Gly was significantly higher than the CTI of RTX in both RA and SLE. In RA, the median (interquartile range) CTI of RTX, OBZ Gly and OBZ was 29 (1350), 60 (4770) and 67 (6077), respectively, and in SLE was 19 (1139), 40 (3153) and 59 (5270), respectively. Both type II anti-CD20 mAbs, OBZ Gly and OBZ, demonstrated superior efficiency of B cell cytotoxicity to the type I anti-CD20 mAb, RTX, in all individual samples from patients with RA and SLE (data not shown). There were no significant correlations between CTI of RTX or CTI of OBZ and patient's age, serum complement and/or IgA levels in samples from patients with SLE (data not shown).
Thus, in both RA and SLE, there was a hierarchy of mAb-induced B cell depletion: RTX < OBZ Gly < OBZ. The superior efficiency of OBZ Gly (having a non-glycomodified Fc similar to RTX) suggests that its type II nature accounts for the difference between the two types of mAbs in the efficiency of B cell depletion in the whole blood assay, whereas the increased efficiency of OBZ compared with OBZ Gly is attributable to afucosylation of the Fc portion.
B-cells internalize RTX more rapidly than OBZ RTX was internalized more extensively than OBZ after 6 h of incubation with a median (range) percentage of surface accessible RTX vs OBZ of 55 (5157) vs 83 (8184), respectively, in RA (n = 5) and 60 (4977) vs 76 (7080), respectively, in SLE (n = 8) (Fig. 1B) . Internalization of RTX and, to a smaller extent, OBZ, was partially inhibited in the presence of the FcgRII-blocking mAb AT10 (Fig. 1B) , similar to our previous observations using a non-glycomodified type II antibody variant [31] . S2 , available at Rheumatology Online) with a median (range) difference of 10.9% (8.121%) whereas the difference for OBZ was 4.8% (0.96.5%) (Fig. 1C) . The mean (S.D.) fold increase in lysed cells in samples incubated with normal healthy serum vs HIS was 1.9 (0.5) and 1.2 (0.2) for RTX and OBZ, respectively (Fig. 1D) . Thus, RTX was superior to OBZ at evoking CDC.
OBZ is more efficient than RTX at activating NK cells
The ability of the mAbs to induce NK cell activation in the whole blood B cell depletion assay, shown in Fig. 2 (Fig. 3B) . NK cell activation, as 3C ) and r 2 = 0.52, P < 0.05 and r 2 = 0.36, P < 0.05, respectively, in SLE (Fig. 3D) . However, correlations were stronger in RA compared with SLE. We next investigated the effect of Fc engineering on activation of NK cells using OBZ Gly and OBZ-PG LALA, which completely lacks FcgR engagement [43] . OBZ was more efficient than OBZ Gly and RTX in depleting B cells in the whole blood assay in both RA (n = 18) and SLE (n = 23) (Fig. 4A) with an increasing hierarchy in the frequency of, and fold-increase in, CD3
À CD56 + CD107a + NK cells as follows: no mAbs = OBZ-PG LALA > RTX > OBZ Gly > OBZ (Fig. 4BD) . The frequency of CD3 À CD56 + CD16 + NK cells was significantly lower in samples incubated with OBZ compared with other samples (Fig. 4D) . The frequency of CD3 À CD56 + CD16 + NK cells was also lower in samples incubated with OBZ Gly compared with RTX in RA, but not SLE (Fig. 4D) . Thus, the ability of mAbs to up-regulate the expression of CD107a on CD3 À
CD56
+ NK cells was greater in RA compared with SLE, such that the mean fold difference in samples incubated with RTX, OBZ-PG LALA, OBZ Gly and OBZ compared with samples incubated without mAbs was 1.2, 1.5, 1.9 and 3.1, respectively, in RA and 1.5, 0.8, 1.4 and 1.8, respectively, in SLE (Fig. 4C) .
OBZ is more efficient than RTX at activating neutrophils Neutrophils have been proposed as mAb effector cells [41] . We assessed the ability of mAbs to induce neutrophil activation by measuring the expression of CD11b and CD62L, as described previously [42] and shown in supplementary Fig. S3 , available at Rheumatology Online. CD11b forms part of the b-integrin (Mac-1) complex and genetic variants of this complex have been associated with lupus-related phagocytic defects [44] . Upon neutrophil activation the surface expression of CD11b is up-regulated whereas the expression of the adhesion molecule CD62L is down-regulated [41, 42] . The MFI of CD11b in samples incubated with mAbs was significantly higher in both RA (n = 10) and SLE (n = 22) (Fig. 5A ) compared with samples incubated without mAbs. In both RA and SLE, we noted significant correlations between the MFI of CD11b in samples incubated without mAbs and that in samples incubated with RTX (r 2 = 0.81, 0.82, respectively) whereas significant correlation for OBZ was noted in SLE (r 2 = 0.81), but not RA (Fig. 5B ). We noted a hierarchy in the ability of mAbs to up-regulate CD11b such that the MFI of CD11b was lower in samples incubated with RTX < OBZ Gly < OBZ, as in the case of NK cell activation. The MFI of CD62L was also greater in samples incubated with RTX > OBZ Gly > OBZ (Fig. 5C ). In both RA and SLE, we noted significant correlations between the MFI of CD62L in samples incubated without mAbs and (Fig. 5D) . Thus, the hierarchy of mAbs in their ability to activate neutrophils was OBZ > OBZ Gly > RTX. Thus, these data indicated that type II mAbs are superior to RTX in activating neutrophils in the whole blood assay in both RA and SLE samples. OBZ-PG LALA did not elicit significant changes for either marker in both RA (n = 7) and SLE (n = 12) compared with samples incubated without mAbs.
OBZ is more efficient than RTX at inducing direct cell death
We assessed DCD, using the Av assay as shown in supplementary Fig. S4 Spearman's correlation coefficient. NT: not treated; OBZ Gly : obinutuzumab with glycosylated Fc; OBZ: obinutuzumab.
subpopulations to mAb-induced DCD and the ability to internalize mAbs or to express CD20 or FcgRIIb.
Discussion
Our data show that OBZ, a type II anti-CD20 mAb with a glycomodified Fc, demonstrated at least 2-fold greater potency at deleting B cells from whole blood samples from patients with RA and SLE compared with RTX. This increased activity of OBZ was effected predominantly through FcgR-mediated effector mechanisms and DCD. In contrast, RTX recruited complement more efficiently for CDC, but was rapidly internalized and significantly less efficient at evoking ADCC and DCD. Our subsequent analysis revealed that the expression of the CD20 target molecule was less on IgD À CD27 + switched memory and DN cells, perhaps accounting for their relative resistance to removal by RTX. Target B cells can be deleted with anti-CD20 mAb through multiple mechanisms, with type I mAb engaging complement more effectively than type II mAb. Our findings of superior efficiency of OBZ over RTX at inducing B cell death, despite its inferior ability to recruit complement, are consistent with previous data derived from in vitro studies on malignant B cells and/or cell lines [22, 28, 45, 46] . The superior efficiency of OBZ in the whole blood assay was noted in all individual samples. Complement defects are characteristic of certain autoimmune conditions, such as SLE [13] , where, we speculate, OBZ may provide a mechanistic advantage over RTX.
The superior efficiency of OBZ in the whole blood assay despite inferior ability to evoke CDC suggests that the predominant mode of action of OBZ is through FcgRmediated effector mechanisms and/or DCD. While there was no difference between patients with RA and SLE in the frequency of activated NK cells that lacked CD16 expression and/or expressed CD107a, NK cells from patients with both RA and SLE responded less well to stimulation with RTX compared with OBZ. We found that activation of NK cells by anti-CD20 mAbs is also associated with down-regulation of CD16 revealing remarkable differences in activation of NK-cell subpopulations based on the relative expression of CD16 and up-regulation of the degranulation marker, CD107a. Whereas RTX was less efficient at activating NK cells in both RA and SLE, OBZ induced a greater fold-increase in activating NK cells   FIG. 4 Obinutuzumab induces superior NK cell-mediated cellular cytotoxicity to rituximab in RA and SLE patient samples www.rheumatology.oxfordjournals.org in samples from patients with RA compared with SLE, suggesting SLE-associated NK cell defects may also contribute to poor depletion with RTX [14, 15, 47] . The relative inefficiency of RTX at evoking ADCC in vitro may, at least partly, be due to internalization of mAbs leading to reduced engagement with FcgR-bearing effector cells, as shown previously [22, 36] . Afucosylation of Fc increases the affinity of IgG1 mAbs for CD16a with little effect on complement binding [48] , which may explain the superior efficiency of OBZ at activating NK cells in the whole blood assay even in the presence of complement [49] . Therefore, the superior efficiency of OBZ at activating NK cells may be attributable to a greater surface accessibility owing to its type II nature and a greater affinity for CD16 conferred by afucosylation of Fc.
Our findings of superior neutrophil activation by OBZ compared with RTX in RA and SLE samples are consistent with studies in malignant B cells [41] . Polymorphisms of CD16b may at least partially account for the variability in mAb-induced activation, most notable for RTX whereas afucosylation may have reduced this variability, as described previously [41] . A number of polymorphisms of CD11b associated with SLE may have contributed to the variability between patients in neutrophil activation [44] , but regardless, glycoengineered OBZ was more efficient than wild type OBZ and RTX at inducing neutrophil activation.
Following from patients with RA and SLE, compared with RTX. These findings are similar to that in malignant B cells [28] .
The main limitations of this study are that all experiments were performed in vitro. Therefore, these results showing superior efficiency of OBZ to RTX may not translate into more efficient B cell depletion in vivo and/or in different tissues such as the lymph node, kidney and joint. Further, concomitant therapies may influence the pharmacokinetics of OBZ and have an impact on its overall efficiency to deplete B cells in patients with RA and SLE.
Disease-and host-associated immune deficiencies may contribute to incomplete depletion with RTX in some patients with RA and SLE leading to worse clinical responses. Phase II clinical studies are on-going to evaluate the efficacy of OBZ in patients with lupus nephritis (NCT02550652) and hypersensitized patients with end-stage renal disease awaiting transplantation (NCT02586051). Our results showing superior efficiency of OBZ over RTX, noted in the whole blood assay, are likely due to FcgR-mediated effector mechanisms and DCD.
This study provides compelling mechanistic reasons for expecting better outcomes with OBZ as an alternative B cell depleting agent for patients with RA, and SLE in particular. College Hospital. The authors would like to thank Eve McLoughlin, Pauline Buck, Nichola Whitbread and 
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